An established, privately-held biotechnology company, Immunicom, Inc. is structured around development of a new technology platform for immuno-oncology and inflammatory disorders. The firm’s highly selective Immunopheresis® blood and/or plasma constituent removal technology is designed effectively to treat a wide variety of cancers and immunological disorders with a safer side-effect profile than conventional treatments. Awarded FDA's Breakthrough Device designation for Stage IV metastatic cancer in 2018, the firm's lead product - LW-02 Column - was awardeed European regulatory clearance (CE Mark certification) in 2021 for use in patients with advanced, refractory, metastatic triple negative breast cancer (TNBC). LW-02 Column Immunopheresis is currently being evaluated in several globally based oncology trials for multiple cancers. Headquartered in San Diego, CA, the firm also has a presence in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turke
